Indication

– Dissolution of cholesterol gallstones in the gallbladder (the gallstones must be radiolucent, and the gallbladder function must be intact), cholestatic liver disease (e.g. primary biliary cirrhosis) and biliary reflux gastritis

– Cystic fibrosis–related liver disease in patients aged 1 month to 18 years (oral suspension only)